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Abstract 
Background: Liver disease, one of the most common causes of hospitalization worldwide, is particularly prevalent in 
Europe. This study aimed to determine the number of hospital discharges and admissions, mortality, premature death 
and costs associated with liver disease from the perspective of the National Health Service in Portugal.
Methods: A descriptive, retrospective analysis of data from 97 hospitals between 2000 and 2008, and mortality data 
for 2011 collected from the Portuguese National Institute of Statistics. The 9th and 10th revisions of the international 
classification of diseases were used to establish diagnoses. National data on demographics, average length of stay, 
in-patient mortality and direct costs associated with hospital admissions and liver transplantation were compared for 
the most common liver diseases. Mortality and premature death were compared using the potential years of life lost 
(PYLL) index.
Results: The annual mean number of discharges for liver disease was 11,503 between 2000 and 2008. Most cases 
of liver disease were diagnosed in men (70.4 %) and the prevalence of liver disease peaked in patients aged from 20 
to 64 years (60.7 %). Alcoholic cirrhosis was the most frequent liver-disease diagnosis leading to discharge (38.6 %). 
In addition, alcoholic cirrhosis emerged as the main cost-driver, accounting for €26,818,930 (42.6 %) of the total cost 
imposed by liver disease. Overall, chronic hepatic disease was the 10th most common cause of mortality in Portugal 
in 2011, causing 21.8 deaths per 100,000. Chronic hepatic disease and hepatocellular carcinoma are even more impor-
tant causes of premature death, ranking third based on PYLL.
Conclusion: In 2011, liver disease was the 10th most common cause of death and the third most important cause 
of premature death in Portugal. Alcohol cirrhosis was the leading cause of liver-related hospital admissions between 
2001 and 2008. It appears that liver disease imposes a considerable social and economic burden on Portugal. Our 
results suggest that educational, legislative and therapeutic interventions to prevent morbidity, mortality and prema-
ture death from liver disease are urgently required to minimise the economic and clinical burdens.
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Background
Liver disease, one of the most common causes of hos-
pitalization worldwide, [1, 2] is particularly prevalent 
in Europe [3]. Indeed, liver disease was the seventh 
most common cause of death in Europe during 2010 
[4]. Chronic hepatitis, cirrhosis and hepatocellular car-
cinoma (HCC) are the most common liver diseases in 
Europe [3, 5]. Viruses and alcohol account for more than 
75 % of cases of liver disease in Portugal [6]. For example, 
cirrhosis frequently causes morbidity and mortality [7–
9], and the direct and indirect financial costs associated 
with liver diseases impose a considerable socioeconomic 
burden on health services and society [10].
Against this background, economic evaluations from 
the perspective of the Portuguese National Health Ser-
vice inform policies to promote prevention and manage-
ment of liver disease and other health problems [1, 2, 
11–14]. However, although health professionals recog-
nize liver diseases as a common cause of morbidity and 
mortality in Portugal [7, 9], few studies estimate the soci-
oeconomic impact. Therefore, our study aims to deter-
mine the profile of patients admitted with liver disease 
between 2001 and 2008, including details of the average 
length of stay (ALOS), mortality among inpatients, and 
direct costs specifically associated with hospital admis-
sions due to liver diseases to the National Health Service 
of Portugal. In addition, to place these results in context, 
we compared mortality and potential years of life lost 
(PYLL) associated with liver disease to those associated 
with other common conditions. This included all national 
deaths to common conditions, occurring both inside and 
outside of hospital, in 2011.
Methods
Population
This descriptive, retrospective analysis uses freely avail-
able admission and discharge data already in the public 
domain, which was obtained from the Portuguese Direc-
torate General for Health or the ‘Direcção Geral de Saude’ 
(DGS). This included data from 97 public hospitals in the 
Portuguese National Health Service categorized using 
diagnosis related-groups (AP21 version) between 2000 
and 2008. This timeframe was decided based on the avail-
able data as the time of data analysis. Patient variables 
(sex, age, mortality and ALOS) were analyzed using Excel 
2003. All patients admitted by liver disease from 2000 to 
2008 were included and their variables (sex, age, mortal-
ity and ALOS) were analyzed using Excel 2003. To iden-
tify the group of inpatients that included liver diseases, 
ICD-codes were used as a filter.
In addition, demographic data and mortality from 
2011 were collected from another source, the Portuguese 
National Institute of Statistics [Instituto Nacional de 
Estatística (INE)] website (http://www.ine.pt) and ana-
lyzed using Excel 2003. This allowed us to quantify the 
mortality associated with liver disease and compare it 
with the mortality associated with other common causes 
of death in Portugal.
Diagnoses of admissions and discharges
Data was obtained from the DGS for the most frequent 
causes of liver diseases (2000–2008) (Table  1), which 
were established using the international classification of 
diseases (ICD) 9th revision, clinical modification, (ICD‐9‐
CM). Using ICD-10 (2008 version), we determined the 
disease categories that caused more deaths than liver dis-
ease in 2011 (Table 2).
Direct costs
We calculated the direct costs paid by Portuguese 
National Health Service for in-patients admitted to all 97 
public hospitals with liver diseases between January 2000 
Table 1 Categories of liver diseases
a Includes: hepatoptosis; alcoholic liver damage unspecified; autoimmune 
hepatitis; toxic hepatitis: hepatitis unspecified
Disease category ICD 9 CM Code
Viral hepatitis 070
HBV 070.3–070.4





Othera 570–573, excluding codes above
Table 2 Categories of  diseases with  greater mortality 
than liver diseases in 2011
Disease category Disease subcategory ICD-10 Code
Cerebrovascular disease I60–I69









Bronchus and lung C33–C34
Motor vehicle traffic accidents V01–V89
Pneumonia J09–J18
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and December 2008. Private institutions do not provide 
data to the DGS, nor is this data in the public domain. 
We also collected ALOS and the amount paid per day 
and for each admission, including medication, examina-
tions, medical and nursing support, from hospital data-
bases (all included in information obtained from the 
DGS). Therefore, this analysis includes the costs associ-
ated with inpatient stay only (e.g., drug costs, nursing, 
consultation and invasive treatment). Ambulatory costs 
were not available and any outpatient costs have not been 
captured. The total costs of inpatient care were produced 
as a function of ALOS and the amount paid per day per 
patient. No adjustment for cost was made depending on 
the reference year.
The authors of this study feel it is important to cap-
ture the costs related to liver transplantation as it is the 
only treatment that solves end-stage liver disease. Costs 
related to liver transplantation were collected and ana-
lyzed separately to the inpatient costs of liver disease 
outlined above. Some other treatments, such as albumin 
dialysis, are used as a bridge to liver transplantation and 
are often performed during the same admission.
Premature death
Lost earnings due to morbidity and premature mortal-
ity is one of the most important drivers of indirect costs 
[15]. Therefore, we collected mortality data for people 
aged 70 years of age and younger, including stratification 
by cause and sex, from INE registries for 2011. Diseases 
considered were classified using ICD-10 codes. Based 
on this, we estimated the PYLL, a summary measure of 
premature mortality which provides an explicit way of 
weighting deaths occurring at younger ages, which are, 
a priori, preventable. The calculation of PYLL involves 
summarising deaths occurring at each age and multiply-
ing this with the number of remaining years to live up 
to a selected age limit. In order to assure cross-country 
comparisons when calculating PYLL, a limit of 70 years is 
used [16]. This is an established method to describe spe-
cific patterns in premature mortality and a mechanism 
for establishing healthcare priorities [17]. In this study, 
PYLL values were calculated for people aged 70 years old 
and under, and those occurring due to liver disease were 
compared to those due to other conditions.
Results
Sample
The mean number of hospital discharges for liver disease 
was 11,503 annually. The number of discharges attrib-
utable to liver disease decreased slightly between 2000 
(11,617) and 2008 (10,503) (Table 3). Cirrhosis remained 
the main cause of admission for liver disease between 
2000 and 2008. Over the same time, discharges due to 
viral hepatitis almost halved (1509 and 674) while dis-
charges for HCC doubled (684 and 1127).
Table  4 summarizes the number of discharges strati-
fied by liver disease. Cirrhosis, mainly caused by alcohol 
abuse, was the most frequent indication leading to dis-
charge (38.6 %), corresponding to 58.2 cases per 100,000 
inhabitants. HCC was the second most common cause 
of hospital discharge, corresponding to 40 cases per 
100,000 inhabitants. In general, males are more likely to 
be discharged with a liver disease than women (70.4 ver-
sus 29.6 %; overall discharge ratio: 2.4:1), with the great-
est sex differences in HCC (3.8:1) and alcoholic cirrhosis 
(3.5:1). In 2008, the proportion of discharged patients 
aged from 20 to 64 years old was highest for hepatitis C 
virus (HCV) (86.9 %), followed by viral hepatitis generally 
Table 3 Number of  discharges diagnosed with  liver dis-
ease between 2000 and 2008
a Includes: hepatoptosis; alcoholic liver damage unspecified; autoimmune 
hepatitis; toxic hepatitis; hepatitis unspecified
Year Number diagnosed with liver disease
Viral hepatitis Cirrhosis HCC Othera All
2000 1509 5313 684 4111 11,617
2001 1317 5821 689 3755 11,582
2002 1744 5995 743 4067 12,549
2003 1599 5770 774 4330 12,473
2004 1399 5637 862 3963 11,861
2005 1087 5530 834 3997 11,448
2006 811 5431 862 3766 10,869
2007 811 5151 912 3752 10,627
2008 674 4769 1127 3933 10,503
Table 4 Number of  discharges by  liver disease categories 
and sex in 2008
a Includes: hepatoptosis; alcoholic liver damage unspecified; autoimmune 
















All 674 6.4 2.0
HBV 210 2.0 2.1
HCV 386 3.7 2.4








HCC 1127 10.7 3.8
Othera 3933 37.4 1.7
All 10,503 100 2.4
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(Fig. 1). Overall, this age group accounted for 60.7 % of 
patients discharged with liver disease in 2008.
ALOS and mortality
The ALOS for liver disease discharges overall and strati-
fied by condition in 2008 was approximately 10  days, 
which showed little variation from 2000 to 2008. How-
ever, Fig.  2 shows that the ALOS for alcoholic cirrho-
sis decreased from 13 to 8  days during this time. In 
2008, HCC and non-alcoholic cirrhosis were associated 
with the highest ALOS. Viral hepatitis had the shortest 
ALOS.
Table 5 shows mortality rates between 2000 and 2008. 
In 2008, HCC emerged as having the highest mortality 
rate among liver diseases (22.6 %), followed by alcoholic 
(14.9  %) and non-alcoholic cirrhosis (13.4  %). Mortality 
rate for all liver disease discharges increased from 10.4 % 
in 2000 to 13.1 % in 2008.
Direct costs of hospital admission
Figure  3 shows the direct hospital costs for in-patients 
for eight disease categories. In 2008, liver disease was 
associated with the third highest amount payed by 
the Public Health Service in terms of hospital admis-
sions (€62,950,631), exceeded by ischemic heart dis-
ease (€167,538,693) and cerebrovascular disease 
(€80,387,569).
Alcoholic cirrhosis emerged as the main cost-driver 
(Table  6), accounting for €26,818,930, 42.6  % of the 
total cost imposed by liver disease. This proportion 
far exceeded the cost imposed by HCC, which was 
€9,737,184 (15.5 %), the second most resource-intensive 
condition. Table  7 shows the direct costs incurred by 
hospitals based on an analysis of 148 liver transplants 
performed during 2008 excluding those associated with 
follow-up visits and transplant-related therapy such as 
immunosuppressive drugs. Again, alcoholic cirrhosis 
and HCC emerged as the main cost-drivers, accounting 
for €5,876,883 (38.5 %) and € 4,330,335 (28.5 %) of overall 
costs associated with liver transplants respectively.
Mortality and premature death
Overall, chronic hepatic disease (which includes cirrhosis 
and HCC) was the 10th most common cause of mortal-
ity in Portugal in 2011, causing 21.8 deaths per 100,000 
inhabitants (Table  8). However, chronic hepatic disease 
and HCC are even more important causes of premature 
death (Table 9), ranking third based on PYLL.
Discussion
Liver disease is one of the most common chronic diseases 
in Portugal. Hospital admissions from hepatic disease 
peak in males aged between 20 and 60 years. This group 
is the most socioeconomically active group in terms of 
contribution to the general economy and to individual 
families in Portuguese society [18, 19]. The high rate of 
liver disease in this group is likely to impose a consider-
able indirect burden on the economy (e.g., through lost 
productivity, benefit payments and lost taxation) and 
families.
The pattern of mortality underscores the economic 
burden imposed by liver disease. Overall, in 2011 liver 
disease was the tenth most common cause of death in 
Portugal. However, hepatic disorders were the third 
most common cause of premature death (i.e., in people 
less than 70 years of age). Therefore, interventions aimed 
at reducing the number of cases of liver disease in this 
group could reduce the socioeconomic burden and mor-
tality imposed by liver disease [20].
This analysis focused on the direct medical costs paid 
by public health insurance due to hospitalization, medi-

























Fig. 1 Proportion (%) of discharges among people aged 20–64 years 















Alcoholic cirrhosis Nonalcoholic cirrhosis
Hepatocellular carcinoma Others
All
Fig. 2 Average length of stay for liver diseases discharges (2000–
2008) (HBV hepatitis B, HCV hepatitis C virus)
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Table 5 Mortality rate for liver diseases discharges (2000-2008)
a Includes: hepatoptosis; alcoholic liver damage unspecified; autoimmune hepatitis; toxic hepatitis; hepatitis unspecified
Year Mortality rate by disease category (%)





2000 0.9 0.9 0.4 13.1 13.4 11.6 26.5 7.8 10.4
2001 1.5 2.3 0.6 14.5 14.4 14.7 26.1 9.4 12.0
2002 1.2 2.0 1.0 14.2 14.7 11.9 24.5 8.7 11.2
2003 1.5 3.3 0.8 13.6 13.4 15.2 28.3 9.3 11.5
2004 1.2 2.8 0.6 13.4 13.4 13.2 25.1 10.6 11.9
2005 1.7 2.3 1.5 13.7 13.7 13.7 26.7 9.5 12.0
2006 1.4 1.5 1.2 14.3 14.4 13.7 25.4 10.4 12.9
2007 2.2 2.1 2.5 15.3 15.1 16.2 24.1 10.8 13.5

















Fig. 3 Direct costs incurred during hospital admissions in 2008
Table 6 Direct costs incurred during  hospital admissions 
for liver diseases in 2008
a Includes: hepatoptosis; alcoholic liver damage unspecified; autoimmune 





Direct costs (€) % of direct costs
Viral hepatitis All 2,647,742 4.2
HBV 820,639 1.3
HCV 1,515,620 2.4










Table 7 Costs per hospital admission related to liver trans-
plant in 2008
a Includes: hepatoptosis; alcoholic liver damage unspecified; autoimmune 





Costs (€)  
relating to liver  
transplant
% of liver  
transplant  
costs
Viral hepatitis All 618,619 4.1
HBV 206,206 1.4
HCV 309,310 2.0










Table 8 Causes of death in Portugal during 2011
Disease category Crude rate/100,000  
of the population
Cerebrovascular disease 125.5
Ischemic heart disease 66.0
Pneumonia 51.4
Diabetes mellitus 43.1
Malignant neoplasm of prostate 36.1
Malignant neoplasm colon and rectum 35.9
Malignant neoplasm of trachea, bronchus  
and lung
35.2
Malignant neoplasm of female breast 29.8
Malignant neoplasm of stomach 23.0
Chronic hepatic disease and cirrhosis/HCC 21.8
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in 2008. Alcoholic cirrhosis was the leading cause of 
liver-related hospital admission and the main cost-driver, 
accounting for €26,818,930. Reducing alcoholic cirrhosis 
through education and legislation could decrease direct 
costs related to hospitalization and liver transplantation. 
The probable reduction in other alcohol-related public 
health problems, as traffic accidents, suggests that our 
analysis underestimates the potential economic, clinical 
and societal impact of tackling alcohol abuse [9, 21, 22]. 
There is evidence supporting the effectiveness and cost-
effectiveness of policies to reduce the impact of alcohol 
consumption. A thorough 2009 review concluded that 
initiating policies that regulate the environment in which 
alcohol is marketed are most effective [23]. In particu-
lar, measures to make alcohol more expensive, limiting 
its availability and regulating advertising practices were 
most cost effective [23]. A more recent report suggested 
that different interventions are more suitable depending 
on the prevalence of hazardous alcohol use, with taxation 
and population-wide interventions most cost-effective 
in settings of high prevalence and targeted interventions 
cost-effective for settings of low prevalence [24]. A report 
as part of the 2005–2007 ELSA (enforcement of national 
laws and self-regulation on advertising and marketing of 
alcohol) project found that Portugal had relatively few 
regulations regarding alcohol marketing compared with 
other European countries and in fact had no procedures 
to monitor these regulations [25]. It should be noted 
that new laws came into force in 2013 in Portugal that 
increased the legal age for the purchasing of spirits to 18.
Chronic hepatitis B virus (HBV) and HCV are, accord-
ing to the International Agency for Research on Can-
cer [26], carcinogens in humans. Between 2 and 5  % of 
patients with liver cirrhosis due to HCV develop HCC 
annually [27] and HBV causes approximately 20  % of 
HCC cases in the western world [28]. In Portugal, the 
number of discharges due to viral hepatitis almost halved 
between 2000 and 2008, whereas the number of HCC 
cases doubled during the same time.
Universal HBV vaccination, introduced in Portugal in 
2000, and improved detection as well as effective and 
well-tolerated treatments for viral hepatitis generally, and 
HBV and HCV in particular, probably contributed to this 
reduction [29, 30].
HBV and HCV that are refractory to treatment can 
progress to decompensated cirrhosis and HCC, result-
ing in high economic costs for public health services [31]. 
Worldwide, liver cancer is the sixth most common malig-
nancy (749,000 new cases a year), the third most com-
mon cause of cancer-related mortality (692,000 deaths a 
year) and accounts for 7 % of all cancers [32]. In Western 
countries, 90  % of people who develop HCC have cir-
rhosis. Viral infection, alcohol, metabolic syndrome and 
immune-mediated conditions (such as primary biliary 
cirrhosis and autoimmune hepatitis) are major risk fac-
tors [33]. In Portugal, HCC imposes a considerable eco-
nomic burden [7]. The socioeconomic burden is even 
higher when liver transplants and premature deaths are 
included. However, new anti-viral therapies reduce long-
term liver complications and, therefore, result in fewer 
hospitalizations and less morbidity [34–38]. Future stud-
ies should assess the impact of these and other new treat-
ments on the morbidity, mortality and socioeconomic 
burden imposed by viral liver diseases.
Although studies from several countries suggest that 
liver disease imposes a considerable socioeconomic 
burden [1–4, 11], no studies quantify costs imposed by 
liver disease in Portugal. This study aimed to provide 
basic data to inform the prioritization of health services. 
Our results show that interventions to prevent morbid-
ity, mortality and premature death are urgently required. 
Tackling risk factors—such as intravenous drug use and 
alcohol consumption, unhealthy nutrition and a sed-
entary lifestyle—should be the main goal to reduce the 
societal, clinical and social toll imposed by liver diseases 
and other chronic non-communicable diseases in Por-
tugal. Our results confirm, for example, that reducing 
alcohol consumption should be a main target of pub-
lic health programmes in Portugal [21, 39]. Against this 
background, managing end-stage liver disease through 
outpatient clinics that focus on compliance and educa-
tion improve patient outcomes [40]. These strategies 
could minimize the direct and indirect costs associated 
with liver disease, particularly premature morbidity and 
mortality.
Our study is subject to certain limitations. Firstly, the 
study does not capture all direct costs from the per-
spective of the Portuguese National Health Service. For 
example, the analysis excludes direct costs imposed 
by ambulatory outpatients, including medication, 
medical consultations, treatments which do not need 
Table 9 Causes of  premature death (less than  70  years 
of age) in Portugal during 2011 based on PYLL
Disease categories Lost life years
Motor vehicle traffic accidents 19,974
Malignant neoplasm of trachea, bronchus and lung 19,880
Chronic hepatic disease and cirrhosis/HCC 17,586
Cerebrovascular disease 14,125
Ischemic heart disease 14,113
Malignant neoplasm of colon/rectal 11,540
Malignant neoplasm of stomach 10,158
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hospitalization and other direct costs incurred by visit-
ing medical institutions. Secondly, the study did not esti-
mate the indirect costs arising from, for example, lost 
workdays and the costs paid by caregivers to support 
the population with liver disease. However, these limita-
tions mean that the study is likely to underestimate the 
costs imposed by liver disease to the Portuguese National 
Health Service and the wider economy. In addition, the 
PYLL index has its limitations, for example, it underesti-
mates the importance of diseases that contribute to, but 
are not recorded as, the underlying cause of death, and 
there is a persistent controversy regarding the definition 
of an upper end point during its calculation.
Conclusions
In 2011, liver disease was the 10th most common cause 
of death and the third most important cause of prema-
ture death in Portugal. Alcohol cirrhosis was the leading 
cause of liver-related hospital admissions between 2001 
and 2008. It appears that liver disease represents a con-
siderable social and economic problem in Portugal. Our 
results suggest that educational, legislative and therapeu-
tic interventions to prevent morbidity, mortality and pre-
mature death from liver disease are urgently required.
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